...
首页> 外文期刊>Molecular and Cellular Probes: The Location, Diagnosis and Monitoring of Disease by Specific Molecules and Cell Lines >NGS-Based genetic testing for heritable cardiovascular diseases. Specific requirements for obtaining informed consent
【24h】

NGS-Based genetic testing for heritable cardiovascular diseases. Specific requirements for obtaining informed consent

机译:基于NGS的遗传心血管疾病的基于遗传学测试。 获得知情同意的具体要求

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical genetic testing in cardiovascular genetic medicine has undergone rapid changes. Next generation sequencing allows simultaneous testing of all genes associated with any cardiovascular phenotype, and molecular genetic testing for multiple genes has become the standard of practice for cardiovascular medicine. While technical and clinical advantages of multigenic approaches are evident, informed consent procedures have become more complex and challenging to the physician ordering such a test, particularly due to the increased potential for unsolicited findings. Based on the EuroGentest "Guidelines for diagnostic next-generation sequencing" we here propose a set of disease-specific requirements for obtaining informed consent for NGS-based genetic testing in a cardiogenetic clinic. We can show that it is often not feasible to obtain informed consent for every detail and suggest, in such cases, to reach general consent beforehand and discuss specific implications of unsolicited findings after the test results are available.
机译:心血管遗传医学中的临床遗传检测经历了快速的变化。下一代测序允许同时测试与任何心血管表型相关的所有基因,以及多种基因的分子遗传检测已成为心血管医学的实践标准。虽然多粒方法的技术和临床优势是明显的,但知情的同意程序对医生订购此类考验具有更复杂,挑战,特别是由于未经请求的发现的潜力增加。基于Eurogentest“诊断下一代测序指南”,我们在此提出了一系列疾病的特定要求,以获得在血管生成诊所中基于NGS的基于基于NGS的基因检测的特定要求。我们可以表明,在这种情况下,在这种情况下,在此情况下,我们往往无法获得知情同意,并建议预先达成一般同意,并在测试结果获得测试结果后讨论未经请求的调查结果的具体影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号